The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including ...

Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, was first approved by the Food and Drug Administration (FDA) for help with chronic weight management and to be used in ...

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

Dr. Todd Ellerin, Vice Chair of Medicine at South Shore Health, talks to WCVB's Ed Harding about the effects popular ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Wegovy is approved to help with weight loss and ... A boxed warning is the most serious warning from the Food and Drug Administration (FDA). It alerts doctors and patients about potentially ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food ...